Abstract
Retinoid X receptors (RXRs) occupy a central position within the nuclear receptor superfamily. They not only function as important transcriptional factors but also exhibit diverse nongenomic biological activities. The pleiotropic actions of RXRs under both physiological and pathophysiological conditions confer RXRs important drug targets for the treatment of cancer, and metabolic and neurodegenerative diseases. RXR modulators have been studied for the purpose of developing both drug molecules and chemical tools for biological investigation of RXR. Development of RXR modulators has focused on small molecules targeting the canonical ligand-binding pocket. However, accumulating results have demonstrated that there are other binding mechanisms by which small molecules interact with RXR to act as RXR modulators. This review discusses the recent development in the design and discovery of RXR modulators with a focus on those targeting novel binding sites on RXR.
Keywords: RXRα, tRXRα, Rexinoid, RXRα modulators, Nongenomic action, Nuclear receptors, NSAID, Apoptosis, Inflammation, PI3K
Current Topics in Medicinal Chemistry
Title:Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor
Volume: 17 Issue: 6
Author(s): Ying Su, Zhiping Zeng, Ziwen Chen, Dan Xu, Weidong Zhang and Xiao-kun Zhang
Affiliation:
Keywords: RXRα, tRXRα, Rexinoid, RXRα modulators, Nongenomic action, Nuclear receptors, NSAID, Apoptosis, Inflammation, PI3K
Abstract: Retinoid X receptors (RXRs) occupy a central position within the nuclear receptor superfamily. They not only function as important transcriptional factors but also exhibit diverse nongenomic biological activities. The pleiotropic actions of RXRs under both physiological and pathophysiological conditions confer RXRs important drug targets for the treatment of cancer, and metabolic and neurodegenerative diseases. RXR modulators have been studied for the purpose of developing both drug molecules and chemical tools for biological investigation of RXR. Development of RXR modulators has focused on small molecules targeting the canonical ligand-binding pocket. However, accumulating results have demonstrated that there are other binding mechanisms by which small molecules interact with RXR to act as RXR modulators. This review discusses the recent development in the design and discovery of RXR modulators with a focus on those targeting novel binding sites on RXR.
Export Options
About this article
Cite this article as:
Su Ying, Zeng Zhiping, Chen Ziwen, Xu Dan, Zhang Weidong and Zhang Xiao-kun, Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor, Current Topics in Medicinal Chemistry 2017; 17 (6) . https://dx.doi.org/10.2174/1568026616666160617092241
DOI https://dx.doi.org/10.2174/1568026616666160617092241 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Insights of CTLA-4 into Its Biological Function in Breast Cancer
Current Cancer Drug Targets Characterization of Breast Lesions by Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS)
Current Medical Imaging The Assessment of Platelet Activation in Antiplatelet Drug Development
Current Medicinal Chemistry Nanoparticulate Drug Delivery in Pregnancy: Placental Passage and Fetal Exposure
Current Pharmaceutical Biotechnology Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design Personalized Diabetes and Cancer Medicine: A Rationale for Anti-Diabetic Nutrition (Bitter Melon) in a Supportive Setting
Current Cancer Therapy Reviews Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Inflammatory Mediators Hold the Key to Dendritic Cell Suppression and Tumor Progression
Current Medicinal Chemistry Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Obesity Modulation - The Role in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Drug Resistance in Childhood Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Aloperine Induces Apoptosis by a Reactive Oxygen Species Activation Mechanism in Human Ovarian Cancer Cells
Protein & Peptide Letters Graphical Abstracts:
Current Cancer Drug Targets Cytokines in Systemic Lupus Erythematosus
Current Molecular Medicine Xanthan Gum and Its Derivatives as a Potential Bio-polymeric Carrier for Drug Delivery System
Current Drug Delivery Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets 21-Hydroxy-6,19-epoxyprogesterone: A Promising Therapeutic Agent and a Molecular Tool for Deciphering Glucocorticoid Action
Mini-Reviews in Medicinal Chemistry Para-Nonylphenol Induces Apoptosis of U937 Human Monocyte Leukemia Cells in vitro
Endocrine, Metabolic & Immune Disorders - Drug Targets An Automated High-Throughput Sample Preparation Protocol for LC-MS/MS Analysis of Glycopeptides
Current Proteomics